PAXIL CR

Compare PAXIL CR  to:
Compare
Compare

Generic Name for PAXIL CR

Paroxetine (as HCl) 12.5mg, 25mg, 37.5mg; controlled-release e-c tabs.

Legal Classification:

Rx

Pharmacological Class for PAXIL CR

SSRI.

Manufacturer of PAXIL CR

GlaxoSmithKline Pharmaceuticals

Indications for PAXIL CR

Panic disorder. Social anxiety disorder.

Adult dose for PAXIL CR

Swallow whole. Give once daily, usually in the AM, adjust by 12.5mg/day at 1-week intervals. Panic disorder: initially 12.5mg/day; max 75mg/day. Social anxiety disorder: initially 12.5mg/day; max 37.5mg/day. Elderly, debilitated, severe hepatic or renal impairment: initially 12.5mg once daily; max 50mg/day.

Children's dosing for PAXIL CR

Not recommended.

Also:

Contraindications for PAXIL CR

Concomitant pimozide, thioridazine (may cause QTc prolongation). During or within 14 days of MAOIs (including linezolid).

Precautions for PAXIL CR

History of seizures (discontinue if occurs), mania/hypomania. Monitor for serotonin syndrome or neuroleptic malignant syndrome-like signs and symptoms; discontinue if occurs. Conditions that affect metabolism or hemodynamic response. Cardiac disease. ECT. Narrow angle glaucoma. Suicidal tendencies (monitor). Write ℞ for smallest practical amount. Avoid abrupt cessation; reduce dose gradually. Reevaluate periodically. Elderly. Labor & delivery. Pregnancy (Cat.D); avoid use. Nursing mothers.

Interactions for PAXIL CR

See Contraindications. Do not start MAOI until at least 2 weeks after discontinuing paroxetine. Concomitant SSRIs, SNRIs, tryptophan: not recommended. Avoid alcohol. Potentiation with other protein bound drugs. Caution with drugs that affect coagulation (eg, warfarin, NSAIDs). Potentiated by cimetidine. Antagonized by fosamprenavir/ritonavir. May affect, or be affected by, drugs metabolized by CYP2D6, including tricyclic antidepressants, fluoxetine, phenothiazines, risperidone, atomoxetine, tamoxifen, Class 1C antiarrhythmics, quinidine. Monitor digoxin, phenytoin, phenobarbital, theophylline, warfarin. Reduce procyclidine dose if anticholinergic effects occur. Caution with triptans, linezolid, lithium, tramadol, St. John's wort or dopamine antagonists; may cause serotonin syndrome (eg, agitation, tachycardia, incoordination, hyperreflexia). Hormonal contraceptives and PMDD treatment: see literature.

Adverse Reactions for PAXIL CR

GI upset, asthenia, sweating, decreased appetite, somnolence, dizziness, insomnia, nervousness, headache, decreased libido, tremor, akathisia, dry mouth, abnormal ejaculation, genital disorders, impotence, hyponatremia, abnormal bleeding, others; serious discontinuation symptoms (monitor); rare: neuroleptic malignant syndrome.

How is PAXIL CR supplied?

CR—30
Tabs 10mg, 30mg, 40mg—30
20mg—30, 90
Susp—250mL

Related Disease:

Anxiety
Obsessive-compulsive disorder
Panic disorder
Social anxiety disorder

Related Resources

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cymbalta approved for maintenance treatment of generalized anxiety disorder (GAD)

November 30, 2009

The FDA has approved Cymbalta (duloxetine HCl, from Lilly) for the maintenance treatment of generalized anxiety disorder (GAD) in adults.

Once-daily venlafaxine extended-release tablets available

August 19, 2009

Osmotica Pharmaceutical and Upstate Pharma, a subsidiary of UCB, have made available venlafaxine extended-release tablets in 37.5mg, 75mg, 150mg, and 225mg dosage strengths.

FDA approves updated labeling for antiepileptic drugs

May 05, 2009

The FDA has approved updated labeling for antiepileptic drugs used to treat epilepsy, psychiatric disorders, and other conditions (eg, migraines, neuropathic pain syndromes).

FDA halts marketing of unapproved nitroglycerin tablets

March 17, 2010

The FDA has ordered Glenmark Generics and Konec Inc. to stop marketing unapproved nitroglycerin tablets.